Vical stops development of skin cancer drug Allovectin

08/13/2013 | Reuters

Vical is halting development of its experimental skin cancer drug Allovectin, its most advanced treatment, based on the findings of a late-stage study. The drug failed to significantly outperform chemotherapy in overall survival and reductions in tumor size in advanced melanoma patients. Vical will focus its resources on development of infectious disease vaccines, CEO Vijay Samant said.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Operating Officer
Health Plan of San Joaquin
French Camp , CA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Children's Health Plan
Houston, TX
Chief Information Officer
Meridian Health Plan
Detroit, MI
NTA Life
Addison, TX
Vice President - Government Products
Health Alliance Plan
Detroit, MI